Volgen
Mark Pogson
Mark Pogson
Onbekend partnerschap
Geverifieerd e-mailadres voor utexas.edu
Titel
Geciteerd door
Geciteerd door
Jaar
Synthetic antibody libraries focused towards peptide ligands
CW Cobaugh, JC Almagro, M Pogson, B Iverson, G Georgiou
Journal of molecular biology 378 (3), 622-633, 2008
772008
Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice
V Greiff, U Menzel, U Haessler, SC Cook, S Friedensohn, TA Khan, ...
BMC immunology 15, 1-14, 2014
662014
Comprehensive Evaluation and Optimization of Amplicon Library Preparation Methods for High-Throughput Antibody Sequencing
U Menzel, V Greiff, TA Khan, U Haessler, I Hellmann, S Friedensohn, ...
PloS one 9 (5), e96727, 2014
662014
Engineering next generation proteases
M Pogson, G Georgiou, BL Iverson
Current opinion in biotechnology 20 (4), 390-397, 2009
662009
Immunogenomic engineering of a plug-and-(dis) play hybridoma platform
M Pogson, C Parola, WJ Kelton, P Heuberger, ST Reddy
Nature communications 7 (1), 12535, 2016
602016
Directed Evolution of Highly Selective Proteases by Using a Novel FACS‐Based Screen that Capitalizes on the p53 Regulator MDM2
TH Yoo, M Pogson, BL Iverson, G Georgiou
ChemBioChem 13 (5), 649-653, 2012
352012
Multi-copy genes that enhance the yield of mammalian G protein-coupled receptors in Escherichia coli
G Skretas, T Makino, N Varadarajan, M Pogson, G Georgiou
Metabolic engineering 14 (5), 591-602, 2012
322012
Proteases that can distinguish among different post-translational forms of tyrosine engineered using multicolor flow cytometry
N Varadarajan, M Pogson, G Georgiou, BL Iverson
Journal of the American Chemical Society 131 (50), 18186-18190, 2009
252009
Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange
W Kelton, AC Waindok, T Pesch, M Pogson, K Ford, C Parola, ST Reddy
Scientific reports 7 (1), 45775, 2017
232017
Crystallographic analyses illustrate significant plasticity and efficient recoding of meganuclease target specificity
R Werther, JP Hallinan, AR Lambert, K Havens, M Pogson, J Jarjour, ...
Nucleic Acids Research 45 (14), 8621-8634, 2017
122017
100 Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML
J Appelbaum, WH Leung, U Martin, K Oda, G Tampella, D Xia, J Zhang, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
22020
Multivalent chimeric antigen receptor
M Pogson
US Patent App. 16/956,107, 2022
12022
Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin
JS Appelbaum, A Price, J Zhang, K Oda, S Sundaram, P Lewis, S Bilic, ...
Blood 138, 905, 2021
12021
Gene editing of TRAC locus utilizing megatal nucleases increases expression of transgenic TCRs delivered via lentiviral vector-mediated gene transfer
MS Magee, I Diaconu, M Pogson, A Gupta, A Jensen-Smith, B Collette, ...
Blood 130, 1906, 2017
12017
Mammalian cell line for protein production and library generation
S Reddy, W Kelton, C Parola, D Mason, M Pogson
US Patent App. 18/329,296, 2023
2023
TCRa HOMING ENDONUCLEASE VARIANTS
J Jarjour, M Pogson
US Patent App. 18/174,165, 2023
2023
Mammalian cell line for protein production and library generation
S Reddy, W Kelton, C Parola, D Mason, M Pogson
US Patent 11,802,281, 2023
2023
TCRα homing endonuclease variants
J Jarjour, M Pogson
US Patent 11,591,582, 2023
2023
CD33 TARGETED IMMUNOTHERAPIES
J Jarjour, M Pogson, W Leung, K Jones, W Crago, A Sanabria, A Hollands, ...
US Patent App. 17/608,743, 2022
2022
CLL-1 TARGETED IMMUNOTHERAPIES
J Jarjour, M Pogson, W Leung, L Rascon, A Sanabria, JC Timmer, ...
US Patent App. 17/608,738, 2022
2022
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20